One solution, developed by PTC Therapeutics Inc. (NASDAQ:PTCT), a US biotechnology company, is to intervene in the transcription process in which the DNA is converted first to messenger RNA and then into protein. PTC Therapeutics Inc. (NASDAQ:PTCT)’s experimental drug ataluren is designed to override the false stop signal by interacting with the ribosome – the tiny biological machine inside every cell that runs along messenger RNA and, following the genetic code, puts together protein. PTC Therapeutics, Inc. (NASDAQ:PTCT) stock performance was -8.06% in last session and finished the day at $15.17. Traded volume was 172,372.00million shares in the last session and the average volume of the stock remained 266.90K shares. PTC Therapeutics, Inc. (NASDAQ:PTCT) insider ownership is 9.00%.

Prosensa Holding N.V. (NASDAQ:RNA) announced that the Company will host a conference call and live audio webcast on Tuesday, May 20, 2014 at 8:00 a.m. US Eastern Time (2:00 p.m. Central European Time) to report its first quarter financial results and provide a corporate update. Prosensa Holding NV (NASDAQ:RNA) dropped -8.36 percent to $6.25 Thursday on volume of 171,560.00million shares. The intra-day range of the stock was $6.18 to $6.91. Prosensa Holding NV (NASDAQ:RNA) has a market capitalization of $224.39million.

Concert Pharmaceuticals, Inc (NASDAQ:CNCE) fell 5% during trading on Wednesday after the company announced weaker than expected quarterly earnings, Analyst Ratings.Net reports. The stock traded as low as $9.30 and last traded at $9.88, with a volume of 78,601 shares changing hands. The stock had previously closed at $10.40. Concert Pharmaceuticals Inc (NASDAQ:CNCE)’s stock on May 15, 2014 reported a decrease of -9.22% to the closing price of $8.66. Its fifty two weeks range is $7.69 -$16.26. The total market capitalization recorded $155.01million. The overall volume in the last trading session was 157,691.00million shares. In its share capital, CNCE has 17.90million outstanding shares.

Investment analysts at Guggenheim decreased their price target on shares of Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) from $15.00 to $13.00 in a note issued to investors on Friday, AnalystRatings.Net reports. Guggenheim’s target price would suggest a potential upside of 129.68% from the company’s current price. On Thursday, shares of Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) dropped -5.05% to close the day at $5.27. Company monthly performance is recorded as -20.03%. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) quarterly revenue growth is -43.52%.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced the appointment of Chris Bowden, M.D., to the newly created position of chief medical officer, where he will oversee global clinical development and regulatory initiatives for Agios. Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock performance was -7.76% in last session and finished the day at $33.18. Traded volume was 296,195.00million shares in the last session and the average volume of the stock remained 463.90K shares. Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider ownership is 15.90%.